不同能量的单波长红光(650nm)控制青少年近视进展的前瞻性多中心随机对照研究

注册号:

Registration number:

ChiCTR2500103524 

最近更新日期:

Date of Last Refreshed on:

2025-05-30 10:46:48 

注册时间:

Date of Registration:

2025-05-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同能量的单波长红光(650nm)控制青少年近视进展的前瞻性多中心随机对照研究

Public title:

Efficiency of Different Power of Single-wavelength Red Light (650 nm) Controls Myopia Progression in Adolescents: a Prospective Multicentre Randomized Controlled Trail

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同能量的单波长红光(650nm)控制青少年近视进展的前瞻性多中心随机对照研究

Scientific title:

Efficiency of Different Power of Single-wavelength Red Light (650 nm) Controls Myopia Progression in Adolescents: a Prospective Multicentre Randomized Controlled Trail

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曾子萌 

研究负责人:

孙旭芳 

Applicant:

Zimeng Zeng 

Study leader:

Xufang Sun 

申请注册联系人电话:

Applicant telephone:

+86 189 7115 9532

研究负责人电话:

Study leader's
telephone:

+86 186 2777 0651

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zzmhusttj@163.com

研究负责人电子邮件:

Study leader's E-mail:

sunxufang2016@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市硚口区解放大道1095号

研究负责人通讯地址:

湖北省武汉市硚口区解放大道1095号

Applicant address:

No. 1095, Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

Study leader's address:

No. 1095, Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

华中科技大学同济医学院附属同济医院眼科

Applicant's institution:

Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究负责人所在单位:

华中科技大学同济医学院附属同济医院眼科

Affiliation of the Leader:

Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TJ-IRB202502142

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

华中科技大学同济医学院附属同济医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

伦理委员会批准日期:

Date of approved by ethic committee:

2025-02-24 00:00:00

伦理委员会联系人:

周璞

Contact Name of the ethic committee:

Pu Zhou

伦理委员会联系地址:

湖北省武汉市硚口区解放大道1095号

Contact Address of the ethic committee:

No. 1095, Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 8366 2379

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

华中科技大学同济医学院附属同济医院

Primary sponsor:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究实施负责(组长)单位地址:

湖北省武汉市硚口区解放大道1095号

Primary sponsor's address:

No. 1095, Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院

具体地址:

湖北省武汉市硚口区解放大道1095号

Institution
hospital:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Address:

No. 1095, Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province

经费或物资来源:

企业、自筹 (湖南唯迪科医疗科技有限公司免费为受试者提供近视弱视综合治疗仪设备)

Source(s) of funding:

Corporate, self-funded (Hunan Weidike Medical Technology Co., Ltd. provides free comprehensive treatment equipment for myopia and amblyopia for subjects)

研究疾病:

近视  

Target disease:

Myopia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

在本研究中,我们拟采用多中心前瞻性随机对照研究方案,以6-18岁青少年近视患者为研究对象,比较在、0.6mW、0.9mW、1.2mW、1.5mW不同功率的低强度红光控制近视进展的有效性,评估短期、中期、长期使用本产品后安全性。  

Objectives of Study:

In this study, we propose to use a multicentre prospective randomised controlled study protocol to compare the efficacy of low-intensity red light at different powers of 0.6mW, 0.9mW, 1.2mW and 1.5mW in controlling the progression of myopia in adolescents and young adults aged 6-18years old suffering from myopia and to assess the safety of the product after short-, medium-, and long-term use.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1、斜视 2、眼科疾病手术史 3、正在使用低浓度阿托品或其他近视防控手段 4、存在全身系统性疾病,光敏感 5、既往使用过红光治疗 6、任一眼有角膜炎、倒睫、外伤等畏光 7、存在任一眼器质性病变:上睑下垂、先天性白内障、先天性眼底病变,圆锥角膜等 8、研究者评估不适用者 9、其它不适合本项研究者

Exclusion criteria:

1. Strabismus 2. History of surgery for ophthalmic diseases 3. Using low concentration atropine or other myopia prevention and control means 4. Presence of systemic systemic diseases, light sensitivity 5. Previous use of red light therapy 6. Either eye has keratitis, inverted eyelashes, trauma and other photophobia 7. Organic lesions in either eye: ptosis, congenital cataract, congenital fundopathy, conical cornea, etc. 8. Those who are not suitable for the study as assessed by the researcher 9. Other unsuitable for the study

研究实施时间:

Study execute time:

From 2025-05-30 00:00:00 To 2026-05-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-05-30 00:00:00 To 2026-05-30 00:00:00

干预措施:

Interventions:

组别:

试验组I组

样本量:

50

Group:

Experimental group I

Sample size:

干预措施:

0.6mW红光治疗

干预措施代码:

Intervention:

0.6mW red light therapy

Intervention code:

组别:

试验组II组

样本量:

50

Group:

Experimental group II

Sample size:

干预措施:

0.9mW红光治疗

干预措施代码:

Intervention:

0.9mW red light therapy

Intervention code:

组别:

试验组III组

样本量:

50

Group:

Experimental group III

Sample size:

干预措施:

1.2mW红光治疗

干预措施代码:

Intervention:

1.2mW red light therapy

Intervention code:

组别:

试验组IV组

样本量:

50

Group:

Experimental group IV

Sample size:

干预措施:

1.5mW红光治疗

干预措施代码:

Intervention:

1.5mW red light therapy

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

佩戴单光眼镜

干预措施代码:

Intervention:

Wear single vision glasses

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三甲 

Institution
hospital:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

中国人民解放军中部战区总医院 

单位级别:

三甲 

Institution
hospital:

Central theater General Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

武汉同济泰康医院 

单位级别:

三甲 

Institution
hospital:

Taikang Tongji (Wuhan) Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

眼轴

指标类型:

主要指标

Outcome:

Axial Length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睫状肌麻痹后等效球镜

指标类型:

次要指标

Outcome:

Spherical equivalent

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

前房深度

指标类型:

次要指标

Outcome:

Anterior chamber depth

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜曲率

指标类型:

次要指标

Outcome:

Corneal curvature

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

裸眼视力

指标类型:

次要指标

Outcome:

Uncorrected visual acuity, UCVA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最佳矫正视力

指标类型:

次要指标

Outcome:

Best corrected visual acuity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼压

指标类型:

次要指标

Outcome:

IOP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

色觉的变化

指标类型:

附加指标

Outcome:

Changes in colour vision

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

后像时间

指标类型:

附加指标

Outcome:

Afterimage time

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中心凹下脉络膜厚度

指标类型:

附加指标

Outcome:

Subcentral Foveal Choroidal Thickness

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

多焦点ERG

指标类型:

附加指标

Outcome:

Multi ERG

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

刺痛

指标类型:

副作用指标

Outcome:

Stinging

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼红

指标类型:

副作用指标

Outcome:

Red eyes

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼底照相

指标类型:

副作用指标

Outcome:

Fundus photography

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

裂隙灯检查

指标类型:

副作用指标

Outcome:

Slit lamp examination

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睫状肌麻痹后柱镜

指标类型:

次要指标

Outcome:

Posterior column lens for ciliary muscle paralysis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睫状肌麻痹后轴位

指标类型:

次要指标

Outcome:

Posterior axial position of ciliary muscle paralysis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 6 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者应用SPSS软件随机数法简单随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

The researcher applied SPSS software random number method for simple random grouping

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,对研究参与者和研究者设盲

Blinding:

Double-blind, blinding the study participants and investigators

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-05-30 10:46:30